Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of <i>ALK</i>-Rearranged NSCLC: <i>ALK</i>- and <i>BRAF</i>-Mutations Followed by Epithelial-Mesenchymal Transition

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of <i>ALK</i>-Rearranged NSCLC: <i>ALK</i>- and <i>BRAF</i>-Mutations Followed by Epithelial-Mesenchymal Transition

<i>Anaplastic lymphoma-kinase (ALK)</i>-rearranged non-small cell lung cancer (NSCLC) is prone to developing heterogeneous, only partly known mechanisms of resistance to ALK-tyrosine-kinase-inhibitors (ALK-TKIs). We present a case of a 38-year old male, who never smoked with disseminated...

Full description

Bibliographic Details
Main Authors: Edyta M. Urbanska, Jens B. Sørensen, Linea C. Melchior, Junia C. Costa, Eric Santoni-Rugiu
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:International Journal of Molecular Sciences
Subjects:
ALK-rearranged NSCLC
crizotinib
ceritinib
alectinib
lorlatinib
ALK-TKI resistance
Online Access:https://www.mdpi.com/1422-0067/21/8/2847

Internet

https://www.mdpi.com/1422-0067/21/8/2847

Similar Items